The management of luminal Crohn’s disease, the most common form of initial presentation of the disease, depends on the location and the severity of the disease. Mild-to-moderate disease represents a relatively large proportion of patients with a first flare of luminal disease, which may also be associated with perianal disease. As quality of life of these patients inversely correlates with disease activity, adequate therapy is a central goal of the overall patient management. Treatment options include mainly sulfasalazine, budesonide and systemic steroids, while the role of mesalazine and antibiotics remains controversial. The role of biological therapies has not been thoroughly evaluated in patients with mild disease.

1.
Michetti P, Juillerat P, Mottet C, Gonvers JJ, Burnand B, Vader JP, Froehlich F, Felley C: Therapy of mild to moderate luminal Crohn’s disease. Digestion 2005;71:13–18.
[PubMed]
2.
Loftus EV Jr, Sandborn WJ: Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:1–20.
[PubMed]
3.
Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J: Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777–782.
[PubMed]
4.
Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J: Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by nod2/card15 genotype. Gut 2003;52:552–557.
[PubMed]
5.
Witte J, Shivananda S, Lennard-Jones JE, Beltrami M, Politi P, Bonanomi A, Tsianos EV, Mouzas I, Schulz TB, Monteiro E, Clofent J, Odes S, Limonard CB, Stockbrugger RW, Russel MG: Disease outcome in inflammatory bowel disease: mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Scand J Gastroenterol 2000;35:1272–1277.
[PubMed]
6.
Cohen RD: The quality of life in patients with Crohn’s disease. Aliment Pharmacol Ther 2002;16:1603–1609.
[PubMed]
7.
Guthrie E, Jackson J, Shaffer J, Thompson D, Tomenson B, Creed F: Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn’s disease. Am J Gastroenterol 2002;97:1994–1999.
[PubMed]
8.
Hanauer SB, Sandborn W: Management of Crohn’s disease in adults. Am J Gastroenterol 2001;96:635–643.
[PubMed]
9.
Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW: National cooperative Crohn’s disease study: results of drug treatment. Gastroenterology 1979;77:847–869.
[PubMed]
10.
Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H: European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249–266.
[PubMed]
11.
Anthonisen P, Barany F, Folkenborg O, Holtz A, Jarnum S, Kristensen M, Riis P, Walan A, Worning H: The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn’s disease. A controlled double-blind study. Scand J Gastroenterol 1974;9:549–554.
[PubMed]
12.
Van Hees PA, Van Lier HJ, Van Elteren PH, Driessen M, Van Hogezand RA, Ten Velde GP, Bakker JH, Van Tongeren JH: Effect of sulphasalazine in patients with active Crohn’s disease: a controlled double-blind study. Gut 1981;22:404–409.
[PubMed]
13.
Singleton JW, Summers RW, Kern F Jr, Becktel JM, Best WR, Hansen RN, Winship DH: A trial of sulfasalazine as adjunctive therapy in Crohn’s disease. Gastroenterology 1979;77:887–897.
[PubMed]
14.
Rijk MC, van Hogezand RA, van Lier HJ, van Tongeren JH: Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial. Ann Intern Med 1991;114:445–450.
[PubMed]
15.
Goldstein F, Farquhar S, Thornton JJ, Abramson J: Favorable effects of sulfasalazine on small bowel Crohn’s disease: a long-term study. Am J Gastroenterol 1987;82:848–853.
[PubMed]
16.
Rasmussen SN, Bondesen S, Nielsen OH, Binder V, Hansen SH, Hvidberg E: 5-Amino-salicylic acid. A review of a new treatment of chronic inflammatory bowel disease (in Danish). Ugeskr Laeger 1985;147:2811–2815.
[PubMed]
17.
Mahida YR, Jewell DP: Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn’s disease. Digestion 1990;45:88–92.
[PubMed]
18.
Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR: A randomized, double-blind, placebo-controlled trial of the oral mesalazine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol 1994;19:278–282.
[PubMed]
19.
Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL: Mesalazine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology 1993;104:1293–1301.
[PubMed]
20.
Singleton J: Second trial of mesalazine therapy in the treatment of active Crohn’s disease. Gastroenterology 1994;107:632–633.
[PubMed]
21.
Hanauer SB, Stromberg U: Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379–388.
[PubMed]
22.
Prantera C, Cottone M, Pallone F, Annese V, Franze A, Cerutti R, Bianchi Porro G: Mesalazine in the treatment of mild to moderate active Crohn’s ileitis: results of a randomized, multicenter trial. Gastroenterology 1999;116:521–526.
[PubMed]
23.
Gross V, Andus T, Fischbach W, Weber A, Gierend M, Hartmann F, Scholmerich J: Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn’s ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. Z Gastroenterol 1995;33:581–584.
[PubMed]
24.
Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E: A comparison of budesonide and mesalazine for active Crohn’s disease. International Budesonide-Mesalazine Study Group. N Engl J Med 1998;339:370–374.
[PubMed]
25.
Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T: Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836–841.
[PubMed]
26.
Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A: Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn’s disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748–1754.
[PubMed]
27.
Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG: The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther 2002;16:1509–1517.
[PubMed]
28.
Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E: Budesonide and mesalazine in active Crohn’s disease: a comparison of the effects on quality of life. Am J Gastroenterol 2002;97:649–653.
[PubMed]
29.
Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG: Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut 1997;41:209–214.
[PubMed]
30.
Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H, et al: A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994;331:842–845.
[PubMed]
31.
Bar-Meir S, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, Reshef R, Odes S, Moshkovitz M, Bruck R, Eliakim R, Maoz E, Mittmann U: Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli Budesonide Study Group. Gastroenterology 1998;115:835–840.
[PubMed]
32.
Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bar U, Weber A, Gierend M, Ewe K, Scholmerich J: Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996;8:905–909.
[PubMed]
33.
Otley A, Steinhart AH: Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2005;4:CD000296.
34.
Tursi A, Giorgetti GM, Brandimarte G, Elisei W, Aiello F: Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn’s disease: an open-label, budesonide-controlled, randomized study. Med Sci Monit 2006;12:PI29–PI32.
35.
Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M, et al: Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 1991;32:1071–1075.
[PubMed]
36.
Ambrose NS, Allan RN, Keighley MR, Burdon DW, Youngs D, Barnes P, Lennard-Jones JE: Antibiotic therapy for treatment in relapse of intestinal Crohn’s disease. A Prospective Randomized Study. Dis Colon Rectum 1985;28:81–85.
[PubMed]
37.
Blichfeldt P, Blomhoff JP, Myhre E, Gjone E: Metronidazole in Crohn’s disease. A double blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123–127.
[PubMed]
38.
Schneider MU, Laudage G, Guggenmoos-Holzmann I, Riemann JF: Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study. Dtsch Med Wochenschr 1985;110:1724–1730.
[PubMed]
39.
Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, Huitfeldt B, Jarnerot G, Krause U, Krook A, Lindstrom B, Nordle O, Rosen A: A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. Ii. Result. Gastroenterology 1982;83:550–562.
[PubMed]
40.
Arnold GL, Beaves MR, Pryjdun VO, Mook WJ: Preliminary study of ciprofloxacin in active Crohn’s disease. Inflamm Bowel Dis 2002;8:10–15.
[PubMed]
41.
Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR: Combined budesonide and antibiotic therapy for active Crohn’s disease: a randomized controlled trial. Gastroenterology 2002;123:33–40.
[PubMed]
42.
Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, Notteghem B, Mary JY: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999;94:674–678.
[PubMed]
43.
Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C: An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328–332.
[PubMed]
44.
Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M: Antibiotic treatment of Crohn’s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23:1117–1125.
[PubMed]
45.
Hanauer SB, Strömberg U: Efficacy of oral Pentasa (r) 4 g/day in treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Gastroenterology 2001;120:2308.
46.
Bassi A, Dodd S, Williamson P, Bodger K: Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471–1478.
[PubMed]
47.
Odes S, Vardi H, Friger M, Wolters F, Russel MG, Riis L, Munkholm P, Politi P, Tsianos E, Clofent J, Vermeire S, Monteiro E, Mouzas I, Fornaciari G, Sijbrandij J, Limonard C, Van Zeijl G, O’Morain C, Moum B, Vatn M, Stockbrugger R: Cost analysis and cost determinants in a European Inflammatory Bowel Disease Inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131:719–728.
[PubMed]
48.
Sandborn WJ, Feagan BG: Review article: mild to moderate Crohn’s disease – defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 2003;18:263–277.
[PubMed]
49.
Vader JP, Froehlich F, Juillerat P, Burnand B, Felley C, Gonvers JJ, Mottet C, Pittet V, Dubois RW, Wietlisbach V, Michetti P: Appropriate treatment for Crohn’s disease: methodology and summary results of a multidisciplinary international expert panel approach – EPACT. Digestion 2006;73:237–248.
[PubMed]
50.
Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, D’Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ: European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006;55(suppl 1):i16–i35.
[PubMed]
You do not currently have access to this content.